Mughal T I, Robinson W A, Thomas M R, Spiegel R
Melanoma Clinic Research Center, University of Colorado Health Sciences Center Denver 80262.
J Cancer Res Clin Oncol. 1988;114(1):108-9. doi: 10.1007/BF00390495.
Following recent reports suggesting that the addition of cimetidine to interferon may enhance response rates in patients with metastatic malignant melanoma, we have completed a Phase II study of the use of recombinant alpha 2 interferon and cimetidine in patients with advanced malignant melanoma and who had progressive disease following interferon therapy alone. We observed two partial responses, no complete responses, and two patients had stable disease. Toxicity encountered was analogous to that of interferon alone. We conclude that the additional of cimetidine to alpha interferon is not beneficial in the treatment of advanced metastatic malignant melanoma.
最近有报道称，在干扰素中添加西咪替丁可能会提高转移性恶性黑色素瘤患者的缓解率，在此之后，我们完成了一项II期研究，该研究针对晚期恶性黑色素瘤患者使用重组α2干扰素和西咪替丁，这些患者在仅接受干扰素治疗后病情仍进展。我们观察到2例部分缓解，无完全缓解，2例患者病情稳定。所遇到的毒性与单独使用干扰素时类似。我们得出结论，在α干扰素中添加西咪替丁对晚期转移性恶性黑色素瘤的治疗并无益处。
